PNPLA3 rs738407: Understanding the Genetic Link to Liver Fat
The rs738407 variant is an intronic marker located within the PNPLA3 gene, which plays a critical role in regulating lipid metabolism in the liver. It is strongly linked to the well-studied I148M protein variant, which is a significant genetic factor associated with the accumulation of fat in the liver.
What each genotype means
Typical liver fat metabolism
This genotype represents the common, wild-type version of the PNPLA3 gene. Research indicates that individuals with this profile do not carry the specific genetic risk factor associated with increased susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD).
This is the most common genotype in many global populations, though frequencies vary significantly by ancestry.
Increased liver fat risk
Carrying one copy of the G allele (often referred to as the I148M variant) is associated with a higher predisposition to hepatic steatosis and the progression of fatty liver disease. This variant is thought to impair normal lipid metabolism in the liver, leading to increased intracellular fat accumulation.
This genotype is common, with the minor allele frequency ranging from approximately 0.20 in African populations to 0.50 in Hispanic populations.
Elevated liver fat risk
Individuals with two copies of the G allele (homozygous for the I148M variant) have a well-documented, significantly increased risk for the entire spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD). Research shows this variant alters lipid droplet biology and mitochondrial function, which can contribute to liver fat retention and potential disease progression.
This genotype is frequently observed in populations with higher minor allele frequencies, particularly among individuals of Hispanic ancestry.
What is the rs738407 Variant?
The rs738407 variant is a single nucleotide polymorphism (SNP) situated within the PNPLA3 gene on chromosome 22. In genetics, an intronic marker like rs738407 sits within a non-coding region of the gene. While it does not directly change the protein sequence itself, it is in strong linkage disequilibrium with the functional I148M variant (rs738409). Linkage disequilibrium means that these two markers are frequently inherited together as a block. Because of this close physical proximity, researchers often use rs738407 as a proxy to study the effects of the PNPLA3 gene on metabolic traits. It serves as a genetic signpost for variations that influence how hepatocytes, or liver cells, process and store triglycerides.
The Role of the PNPLA3 Gene
The PNPLA3 gene encodes a protein known as patatin-like phospholipase domain-containing protein 3. This protein is primarily associated with lipid droplets and intracellular membranes within liver cells. Its normal function involves the regulation of lipid metabolism, specifically the breakdown and storage of triglycerides. When the gene carries the I148M mutation—which is closely linked to the rs738407 marker—the resulting protein exhibits altered activity. Research suggests this mutant protein may sequester other enzymes or interfere with normal lipolytic processes, leading to an accumulation of fat within the liver. This disruption in lipid homeostasis is a central focus of studies investigating metabolic dysfunction-associated steatotic liver disease (MASLD).
Research Associations and Evidence
The association between PNPLA3 variants and liver fat content is well-documented in the scientific literature. Large-scale genome-wide association studies (GWAS) have consistently identified this locus as a primary genetic determinant for hepatic fat fraction and the progression of liver-related conditions. The evidence is considered strong regarding the variant's role in modulating liver fat accumulation. However, it is important to note that while the genetic association is robust, the clinical manifestation of liver disease is complex and influenced by a combination of genetics, diet, lifestyle, and other environmental factors. Current research is ongoing to determine the exact mechanisms by which the I148M variant drives cellular stress and lipid storage, as well as how these findings might eventually inform future therapeutic interventions.
Population Frequency
The frequency of the PNPLA3 variant alleles varies significantly across different ancestral populations. Data from large-scale genomic databases indicate that the minor allele frequency for markers in this region ranges from approximately 0.20 in populations of African descent to as high as 0.50 in Hispanic populations. This wide distribution highlights that the genetic predisposition to higher hepatic fat storage is common across many global groups. Understanding these frequency differences is essential for researchers when conducting population-based studies, as it helps contextualize why certain groups may show higher rates of specific metabolic traits related to liver health.
Interpreting Your Genetic Information
Genetic information regarding the PNPLA3 variant provides insight into your biological predisposition toward lipid metabolism, but it is not a diagnostic tool. Having a specific genotype does not guarantee the development of any liver condition, nor does it mean you are immune to one. Liver health is heavily influenced by modifiable factors such as nutrition, physical activity, and alcohol consumption. If you are concerned about your liver health or have questions about your genetic results, it is important to discuss them with a healthcare professional or a genetic counselor. They can help you interpret these findings in the context of your overall health history and provide guidance on appropriate screenings or lifestyle adjustments.
How common is this variant?
The minor allele frequency for this variant ranges from 0.20 in African populations to 0.50 in Hispanic populations, reflecting significant diversity in its prevalence.
Frequently asked questions
Does having the PNPLA3 variant mean I have liver disease?
No, having this variant does not mean you have liver disease. It is a genetic marker associated with a predisposition to higher liver fat, but many other factors like diet and lifestyle play a much larger role in your actual health.
Can I change my PNPLA3 genotype?
No, your genotype is determined at conception and cannot be changed. However, you can manage your health through lifestyle choices that support liver function regardless of your genetic makeup.
Should I get tested for the PNPLA3 variant?
Genetic testing for this variant is generally not recommended for routine clinical care. If you have concerns about your liver health, you should consult a doctor for standard clinical tests like blood work or imaging.
Is this variant related to alcohol-related liver disease?
Research indicates that PNPLA3 variants are associated with the spectrum of fatty liver disease. You should discuss your specific health risks and the impact of alcohol consumption with your primary care physician.
Sources & further reading
Educational information only, last refreshed 9/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs738407?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PNPLA3
The p.Ile148Met variant in PNPLA3 is a major genetic determinant of hepatic fat content and NAFLD risk.
Intronic regulatory variant in linkage disequilibrium with I148M associated with hepatic fat fraction and ALT levels.
The PNPLA3 S453I variant is a rare variant associated with hepatic lipid metabolism; note that the common risk variant for NAFLD is rs738409.
An intronic variation in linkage disequilibrium with the major PNPLA3 non-alcoholic fatty liver disease (NAFLD) locus that contributes to individual liver fat accumulation and fibrosis predisposition.
The PNPLA3 I148M variant is a major genetic risk factor for non-alcoholic fatty liver disease (NAFLD) and progression to cirrhosis.
This variant is associated with increased risk of non-alcoholic fatty liver disease and liver fat accumulation.